Hi guys. Can I check my understanding/the implications of this funding deal.
It seems that none of the money needs to be returned to Carlyle unless they actually get through phase 3 and start selling their drug. Then it caps out at 4 times the funded amount i.e. 480-640 US million. Implication is that Carlyle must think there is a Greater then 25% chance of getting 4x their money back, probably with a good margin of safety as well, otherwise they wouldn't have agreed to this funding deal, because they risk throwing $120 million down the toilet. Am I correct in this reading of the deal?
Ann: Opthea secures up to US$170m in non-dilutive financing, page-18
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.020(4.04%) |
Mkt cap ! $584.7M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 50.8¢ | 47.5¢ | $4.304M | 9.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 29597 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 15044 | 2 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |